Assessment of the 12-Lead ECG as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People
Published: September 15, 2014
- Mandatory and universal cardiovascular mass screening with 12-lead ECGs in large general populations of young healthy people 12-25 years of age to identify genetic/congenital and other cardiovascular abnormalities is not recommended for athletes and non-athletes alike.
- Consideration for large-scale, general population and universal cardiovascular screening in the age group 12 to 25 years with history–taking and physical examination alone is not recommended.
- Use by examiners of the AHA 14-point elements and those from other societies as a part of comprehensive history–taking and physical examination to detect or raise suspicion of genetic/congenital and other cardiovascular abnormalities is recommended for cardiovascular screening in young people aged 12 to 25 years.
Supporting Materials
Recommended Reading
- Key Concepts in the Evaluation of Screening Approaches for Heart Disease in Children and Adolescents
- Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update
- Role of Pulse Oximetry in Examining Newborns for Congenital Heart Disease